Friday, October 24, 2025

10:35 AM - 11:20 AM

---

Details

The latest analysis of new medicine launches highlights a key shift, with emerging biopharmaceutical companies driving both a growing share of innovation and commercial launches. In tandem, 2024 has seen large pharmaceutical companies increasingly in-license late-stage assets that are nearing approval. Together, these trends signal a clear imperative for biotech companies: to realise their full value, they must be prepared to take products all the way to market and strategically position themselves for successful commercial launches. This means shaping clinical development with an eye toward optimising pricing and reimbursement outcomes and choosing the commercialisation model that best fits their strengths - whether it is direct market entry, strategic partnership, or out-licensing. Join our panel discussion as we explore: • A biotech company’s experience aligning clinical development with market access strategy • A pharmaceutical leader’s perspective on in-licensing decisions • A market access assessor’s experience in decision-making for medicines reimbursement Gain actionable insights and uncover what it takes to go from breakthrough science to commercial success

---

Speaker